274 related articles for article (PubMed ID: 22500680)
1. The role of abiraterone in the management of metastatic castration-resistant prostate cancer.
Rawlinson A; Mohammed A; Beatty J; Bell R; Miller M
Expert Rev Anticancer Ther; 2012 Apr; 12(4):429-37. PubMed ID: 22500680
[TBL] [Abstract][Full Text] [Related]
2. Abiraterone for the treatment of metastatic castrate-resistant prostate cancer.
Beckett RD; Rodeffer KM; Snodgrass R
Ann Pharmacother; 2012; 46(7-8):1016-24. PubMed ID: 22714819
[TBL] [Abstract][Full Text] [Related]
3. Maximizing survival in metastatic castrate-resistant prostate cancer: a clinical viewpoint.
Birtle A
Expert Rev Anticancer Ther; 2013 Jan; 13(1):89-99. PubMed ID: 23259430
[TBL] [Abstract][Full Text] [Related]
4. The role of enzalutamide in the treatment of castration-resistant prostate cancer.
Rawlinson A; Mohammed A; Miller M; Kunkler R
Future Oncol; 2012 Sep; 8(9):1073-81. PubMed ID: 23030482
[TBL] [Abstract][Full Text] [Related]
5. Abiraterone acetate for castration resistant prostate cancer.
Shah S; Ryan C
Expert Opin Investig Drugs; 2010 Apr; 19(4):563-70. PubMed ID: 20225998
[TBL] [Abstract][Full Text] [Related]
6. New therapies for castration-resistant prostate cancer: efficacy and safety.
Beltran H; Beer TM; Carducci MA; de Bono J; Gleave M; Hussain M; Kelly WK; Saad F; Sternberg C; Tagawa ST; Tannock IF
Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649
[TBL] [Abstract][Full Text] [Related]
7. Agents that target androgen synthesis in castration-resistant prostate cancer.
Ferraldeschi R; de Bono J
Cancer J; 2013; 19(1):34-42. PubMed ID: 23337755
[TBL] [Abstract][Full Text] [Related]
8. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
MacVicar GR; Hussain MH
Curr Opin Oncol; 2013 May; 25(3):252-60. PubMed ID: 23511665
[TBL] [Abstract][Full Text] [Related]
9. Abiraterone acetate for the treatment of prostate cancer.
Ryan CJ; Cheng ML
Expert Opin Pharmacother; 2013 Jan; 14(1):91-6. PubMed ID: 23199349
[TBL] [Abstract][Full Text] [Related]
10. Zibotentan for the treatment of castrate-resistant prostate cancer.
Shepard DR; Dreicer R
Expert Opin Investig Drugs; 2010 Jul; 19(7):899-908. PubMed ID: 20497097
[TBL] [Abstract][Full Text] [Related]
11. Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer.
Agarwal N; Hutson TE; Vogelzang NJ; Sonpavde G
Future Oncol; 2010 May; 6(5):665-79. PubMed ID: 20465382
[TBL] [Abstract][Full Text] [Related]
12. Novel concepts in androgen receptor blockade.
Hsieh AC; Ryan CJ
Cancer J; 2008; 14(1):11-4. PubMed ID: 18303477
[TBL] [Abstract][Full Text] [Related]
13. Abiraterone acetate in castration-resistant prostate cancer.
Iacovelli R; Palazzo A; Procopio G; Gazzaniga P; Cortesi E
Anticancer Drugs; 2012 Mar; 23(3):247-54. PubMed ID: 22123334
[TBL] [Abstract][Full Text] [Related]
14. Abiraterone acetate: a novel drug for castration-resistant prostate carcinoma.
Nandha R
J Postgrad Med; 2012; 58(3):203-6. PubMed ID: 23023354
[TBL] [Abstract][Full Text] [Related]
15. Emerging and second line therapies for the management of metastatic castration-resistant prostate cancer: the Australian perspective.
Parente P; Parnis F; Gurney H
Asia Pac J Clin Oncol; 2012 Mar; 8(1):31-42. PubMed ID: 22369442
[TBL] [Abstract][Full Text] [Related]
16. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
17. Targeting continued androgen receptor signaling in prostate cancer.
Massard C; Fizazi K
Clin Cancer Res; 2011 Jun; 17(12):3876-83. PubMed ID: 21680543
[TBL] [Abstract][Full Text] [Related]
18. A new era for castrate resistant prostate cancer: a treatment review and update.
Fong MK; Hare R; Jarkowski A
J Oncol Pharm Pract; 2012 Sep; 18(3):343-54. PubMed ID: 22343966
[TBL] [Abstract][Full Text] [Related]
19. Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer.
Armstrong AJ; George DJ
Prostate Cancer Prostatic Dis; 2010 Jun; 13(2):108-16. PubMed ID: 20066005
[TBL] [Abstract][Full Text] [Related]
20. Update on castrate-resistant prostate cancer: 2010.
Lassi K; Dawson NA
Curr Opin Oncol; 2010 May; 22(3):263-7. PubMed ID: 20177381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]